Why Keytruda Stops Working: Overcoming Tumor Microenvironment Immunotherapy Resistance

By Editorial Team

Originally compiled for translational precision oncology tracking. References to clinical registries provided inline.

Pembrolizumab (Keytruda) has fundamentally shifted the treatment paradigm for advanced malignancies by blocking the Programmed Death-1 (PD-1) receptor. However, clinical data shows that up to 60–70% of patients experience either primary resistance (lack of initial response) or adaptive secondary resistance (progression after a period of response).

Accumulating clinical evidence points to the Tumor Microenvironment (TME) as the principal driver of this therapeutic failure. This review synthesizes the cell-extrinsic and cell-intrinsic mechanisms within the TME that neutralize cytotoxic T-cell activity and maps out strategic metabolic and microenvironmental interventions to restore anti-PD-1 sensitivity.

1. Introduction: The Mechanism of Immune Checkpoint Blockage (ICB)

The therapeutic rationale behind pembrolizumab relies on a simple premise: unmasking hidden tumors. Under physiological conditions, the interaction between the PD-1 receptor on T-cells and its ligands (PD-L1/PD-L2) on tumor cells acts as an immune "off-switch," preventing autoimmune destruction. Keytruda binds to PD-1, preventing this interaction and allowing cytotoxic CD8+ T-lymphocytes to recognize and destroy malignant cells.

Cold vs Hot Tumors Explained: Why the Tumor Microenvironment Determines Immunotherapy Success

However, a tumor is not merely a collection of isolated clonal cells; it is an organized, dynamic ecosystem. Even when pembrolizumab successfully removes the PD-1 brake, the surrounding microenvironment can physically and chemically shut down incoming T-cells before they ever reach their targets.

2. Cell-Extrinsic Drivers of Anti-PD-1 Resistance

Resistance to immunotherapy can be broadly categorized into tumor-intrinsic alterations (such as losing MHC-I expression) and tumor-extrinsic microenvironmental factors. The extrinsic components act as active shields, disarming incoming T-cells through multiple vectors:

A. Cellular Shields: MDSCs, TAMs, and Tregs

  • Myeloid-Derived Suppressor Cells (MDSCs): These immature myeloid cells actively deplete localized L-arginine through the expression of Arginase-1. Without arginine, incoming T-cells lose their structural ability to proliferate.
  • Tumor-Associated Macrophages (TAMs / M2 Phenotype): M2-polarized macrophages secrete high levels of Transforming Growth Factor-beta (TGF-β) and Interleukin-10 (IL-10), downregulating the antigen presentation machinery.
  • Regulatory T-Cells (Tregs): Tregs act as metabolic sinks, absorbing vital Interleukin-2 (IL-2) via high-affinity CD25 receptors, effectively starving cytotoxic T-cells of necessary growth factors.

B. The Metabolic Shield: Hypoxia and Extracellular Acidification

Malignant cells rely heavily on accelerated glycolysis—even in the presence of oxygen—a phenomenon known as the Warburg Effect. This rapid metabolic rate creates a hostile chemical zone:

  1. Glucose Deprivation: Tumors consume the vast majority of local glucose, leaving migrating CD8+ T-cells without the raw fuel required for effector function.
  2. Lactate Overproduction: The end product of this glycolytic surge is lactic acid, pumped out into the extracellular matrix via monocarboxylate transporters (MCTs). This drops the localized TME pH to an acidic 6.2–6.8, which freezes T-cell motility and halts the secretion of Interferon-gamma (IFN-γ).

C. The Physical Barrier: Extracellular Matrix (ECM) Remodeling

Cancer-associated fibroblasts (CAFs) lay down a dense, hyper-crosslinked network of collagen and hyaluronic acid. This dense physical network creates high interstitial fluid pressure (IFP) that compresses local blood vessels. As a result, pembrolizumab molecules and therapeutic lymphocytes are physically blocked from penetrating deep into the core of solid tumors.

3. Strategic Interventions: Overcoming the TME Barrier

To overcome Keytruda resistance, clinical protocols must shift from monotherapy to combinations that target these specific TME vulnerabilities.

TME Resistance Factor Proposed Therapeutic Mechanism Targeted Agent / Clinical Class
Angiogenesis & Vessel Collapse VEGF inhibition to normalize vessels and improve T-cell entry Lenvatinib / Bevacizumab
Extracellular Acidification MCT4 inhibitors or systemic alkalization to restore neutral TME pH Metabolic modifiers / Buffer therapies
TGF-β Mediated Fibrosis Blocking CAF activation to open physical channels in the ECM Galunisertib (TGF-βR1 inhibitor)
Adenosine Accumulation Inhibiting CD39/CD73 enzymes to prevent ATP-to-adenosine conversion Small-molecule ectonucleotidase inhibitors

4. Conclusion & Clinical Outlook

Primary and adaptive resistance to pembrolizumab is rarely a failure of the drug itself; rather, it is a testament to the evolutionary adaptability of the tumor microenvironment. By deploying targeted strategies—such as combining anti-angiogenic agents to lower interstitial pressure, or implementing metabolic interventions to neutralize extracellular lactic acid—oncologists can successfully turn "cold" microenvironments "hot" again, restoring Keytruda’s original therapeutic capacity.

References & Literature Review Basis

  1. Chen, T.-H., Chang, P. M.-H., & Yang, M.-H. (2021). Combination of pembrolizumab and lenvatinib is a potential treatment option for heavily pretreated recurrent and metastatic head and neck cancer. Journal of the Chinese Medical Association, 84(4), 361–367. https://doi.org/10.1097/jcma.0000000000000497
  2. Mimura, K., Shimomura, A., Gota, T., et al. (2022). Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer. Gynecologic Oncology Reports, 44, 101084. https://doi.org/10.1016/j.gore.2022.101084
  3. Tian, L.-R., Lin, M.-Z., Zhong, H.-H., et al. (2022). Nanodrug regulates lactic acid metabolism to reprogram the immunosuppressive tumor microenvironment for enhanced cancer immunotherapy. Biomaterials Science, 10(14), 3892–3900. https://doi.org/10.1039/d2bm00650b
  4. Wang, Z., & Wu, X. (2020). Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker. Cancer Medicine, 9(21), 8086–8121. https://doi.org/10.1002/cam4.3410
  5. Zielińska, M. K., Ciążyńska, M., Sulejczak, D., et al. (2025). Mechanisms of Resistance to Anti-PD-1 Immunotherapy in Melanoma and Strategies to Overcome It. Biomolecules, 15(2), 269. https://doi.org/10.3390/biom15020269
  6. Zhuang, Y., Liu, C., Liu, J., & Li, G. (2020). Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle. OncoTargets and Therapy, 13, 83–94. https://doi.org/10.2147/ott.s239398
From SmartCancer.org

Comments

Post a Comment

Popular posts from this blog

Ivermectin for Cancer Treatment: Protocols and Evidence (2026 Update)

By Editorial Team
Image
Ivermectin is a drug primarily used to treat parasitic infections, and it has attracted research interest for its potential biological effects in cancer models, particularly within integrative and experimental treatment contexts. Supporters point to hundreds of preclinical studies and case reports showing anti-tumor activity across multiple cancer types.  However, current mainstream oncology guidelines do not support ivermectin as a standard or evidence-based treatment for cancer, especially as a substitute for established therapies such as immunotherapy, targeted therapy, chemotherapy, or radiotherapy. So where does the truth lie? The answer is more nuanced than either side often suggests. Access to modern cancer care remains uneven globally. Advanced diagnostic testing, molecular profiling, and novel therapies are often more accessible in high-income healthcare systems or through comprehensive insurance coverage. In contrast, patients in lower-resource or impoverished settings m...
Read more

Fenbendazole and the Joe Tippens Protocol: Evidence, Risks, and Current Perspective (2026 Update)

By Editorial Team
Image
Introduction The Joe Tippens Protocol revolves around the off-label use of fenbendazole (a veterinary dewormer commonly sold as Panacur C or Safe-Guard) combined with various supplements for cancer. The Protocol has been gaining rapid interest over the past years following some  fenbendazole advanced cancer success stories . Joe Tippens popularized this approach after claiming it contributed to his remission from metastatic small-cell lung cancer in 2017. As of 2026, Joe Tippens remains alive and reports being cancer-free for over 8 years, continuing a maintenance version of the protocol. Fenbendazole is marketed for animals (e.g., Panacur C, Safe-Guard ) and has no regulatory approval for human cancer treatment . Evidence for anticancer effects is primarily preclinical or anecdotal , and clinical trials in humans are lacking. Important Disclaimer: Fenbendazole is not approved by the FDA, EMA, or any regulatory body for human use or canc...
Read more

Fenbendazole and Ivermectin for Cancer: A Case Series of Over 700 Patients (2026)

By Editorial Team
Image
Medically Reviewed | Last updated on June 28, 2026. Anecdotal reports and preliminary studies suggest that ivermectin and fenbendazole, both antiparasitic drugs, may have potential anticancer effects when used alongside other treatments.  Many people immediately dismiss the potential of ivermectin and fenbendazole when they learn it is “horse or dog medicine”. That initial reaction is overcome when genuine human success stories are told including the lack of serious side effects. The testimonials you are about to read are from individuals who have bravely shared their experiences in the hope of inspiring and uplifting others. These are raw human accounts, unfiltered by gatekeepers—not peer-reviewed studies—but they offer insights that may be valuable to those searching for options. Repurposed Cancer Therapies Case Reports Explorer Interactive tracking dashboard compiling 766 reported case studies across 21 fields. Click any card to jump directly to its dedicated arti...
Read more

Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

By Editorial Team
Image
Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...
Read more

Top 10 Cancer Fighting Supplements: Evidence Based Literature Review (2026 Update)

By Editorial Team
Image
Are you overwhelmed by conflicting advice on cancer, diet, and supplements ? You’re not alone. With so many claims out there, it’s hard to separate fact from fiction . Can certain foods lower your cancer risk ? Are some foods increasing it without you realizing? What about vitamin and mineral supplements —do they help prevent cancer, or could they actually increase your risk ? The term " anti-cancer supplements " can be misleading. While some nutrients support the body in cancer prevention or treatment, others may interfere with therapies or even pose risks. There are presently over 1,500 herbs and food supplements in commerce, many of them with claims in use against cancer. This guide compiles over 500 scientific r...
Read more

Dr. William Makis's Recommended Ivermectin Dosages for Cancer (2026)

By Editorial Team
Image
Last revised: June 2026 Integrative Oncology · Protocol Review A comprehensive synthesis of Dr Makis's clinical dosing regimens, benzimidazole combination strategies, the 2026 Hulscher observational cohort, pharmacokinetic rationale, safety monitoring requirements, and anonymised patient outcome data — presented with evidence grading. OneDayMD Editorial Team  |  Medically reviewed and updated  |  About Us Abstract Background: Dr William Makis MD (McGill Medicine; 110+ peer-reviewed publications) has treated cancer patients using repurposed antiparasitic agents since 2023, publicly documenting protocols and outcomes via Substack and X (@MakisMD). His approach centres on high-dose ivermectin combined with benzimidazoles and metabolic interventions, customised by cancer type and stage. Purpose: This continuously updated review synthesises Dr Makis's publishe...
Read more

Fenbendazole and Cancer: What the Science Really Shows (Evidence, Risks & Open Questions)

By Editorial Team
Image
Abstract Background:  Fenbendazole (FBZ), a benzimidazole anthelmintic approved for veterinary use, has attracted attention for potential anticancer activity based on laboratory findings and widespread anecdotal reports.  Objective:  To critically appraise the current evidence on fenbendazole and cancer using a peer‑review style framework.  Methods:  Narrative review of preclinical studies, publicly reported human case narratives, and safety signals, with emphasis on evidence hierarchy and translational limitations.  Results:  Preclinical data demonstrate antiproliferative effects via microtubule disruption and metabolic stress in vitro and in animal models. Human evidence is limited to uncontrolled case reports; no Phase I–III clinical trials or regulatory approvals for oncology exist. Safety data in humans are sparse, with hepatotoxicity signals reported.  Conclusions:  Fenben...
Read more

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2026)

By Editorial Team
Image
Fenbendazole and ivermectin, both antiparasitic drugs that have shown potential in cancer treatment through several mechanisms, such as slowing cancer cell growth and boosting the immune response. Fenbendazole is being studied for its ability to disrupt energy production in cancer cells, effectively hindering their growth. Ivermectin, on the other hand, has been explored in combination with checkpoint inhibitors to boost the immune system's response to tumors—especially in challenging cases like triple-negative breast cancer. Introduction Cancer remains a leading cause of morbidity and mortality worldwide, with an increasing incidence of aggressive and treatment-resistant tumors such as triple-negative breast cancer (TNBC), pancreatic adenocarcinoma, and glioblastoma. Despite significant advances in targeted therapies and immunotherapies, many patients continue to face limited effective options, highlighting an urgent need for novel, affordable, and accessible treatment strategies....
Read more

Fenbendazole vs Ivermectin for Cancer: Differences and Which Is Better?

By Editorial Team
Image
Medically Reviewed | Last updated on May 30, 2026. Cancer patients are increasingly inquiring about the use of the anthelmintic drugs Fenbendazole (FenBen) and Ivermectin (IVM) as potential treatments for cancer. Notably, these patients typically fall into two distinct groups, neither of which represents the usual stage 1 or 2 cancer cases where conventional therapies often show promise. The first group consists of older men whose lung or prostate cancer has recurred. Having undergone conventional treatments previously without success, they express skepticism about its effectiveness this time around. The second, larger group comprises younger patients under 40 dealing with aggressive breast cancer, colorectal cancer, or lymphoma—forms of early-onset cancers that appear to lack the typical mutations observed in traditional cases. This article aims to delve into the differences between Fe...
Read more

Fenbendazole and Ivermectin for Stage 4 Pancreatic Cancer: A Compilation of Case Reports and Mechanistic Insights (2026)

By Editorial Team
Image
OneDayMD  |  Integrative Oncology Review ISSN (Online) pending  •  Volume 1, Issue 1  •  Published: 10 August 2025  •  Updated: 15 June 2026 Case Series & Mechanistic Review Compiled tumour marker responses, radiologic outcomes, and mechanisms of anti-cancer action across an international patient cohort Last updated: 15 June 2026 DOI: pending  •  Cite as: OneDayMD Editorial Team. Antiparasitic Drug Repurposing in Stage 4 PDAC: A Compiled Case Series of 28 Patients. OneDayMD Integr Oncol Rev. 2025;1(1). Updated June 2026. Evidence Classification All case reports in this series represent CEBM Level 4–5 evidence (case reports and expert opinion). This compilation is hypothesis-generating. No randomised controlled trials of ivermectin, fenbendazole, or mebendazole for pancreati...
Read more

Archive

Show more